title: Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.
abstract: BACKGROUND
  The generation of new immunogens able to elicit strong specific immune responses remains a major challenge in the attempts to obtain a prophylactic or therapeutic vaccine against HIV/AIDS. We designed and constructed a defective recombinant virus based on the HIV-1 genome generating infective but non-replicative virions able to elicit broad and strong cellular immune responses in HIV-1 seropositive individuals.
  
  
  RESULTS
  Viral particles were generated through transient transfection in producer cells (293-T) of a full length HIV-1 DNA carrying a deletion of 892 base pairs (bp) in the pol gene encompassing the sequence that codes for the reverse transcriptase (NL4-3/ΔRT clone). The viral particles generated were able to enter target cells, but due to the absence of reverse transcriptase no replication was detected. The immunogenic capacity of these particles was assessed by ELISPOT to determine γ-interferon production in a cohort of 69 chronic asymptomatic HIV-1 seropositive individuals. Surprisingly, defective particles produced from NL4-3/ΔRT triggered stronger cellular responses than wild-type HIV-1 viruses inactivated with Aldrithiol-2 (AT-2) and in a larger proportion of individuals (55% versus 23% seropositive individuals tested). Electron microscopy showed that NL4-3/ΔRT virions display immature morphology. Interestingly, wild-type viruses treated with Amprenavir (APV) to induce defective core maturation also induced stronger responses than the same viral particles generated in the absence of protease inhibitors.
  
  
  CONCLUSIONS
  We propose that immature HIV-1 virions generated from NL4-3/ΔRT viral clones may represent new prototypes of immunogens with a safer profile and stronger capacity to induce cellular immune responses than wild-type inactivated viral particles.
authors.affiliation: Institut dInvestigations Biomèdiques August Pi i Sunyer (IDIBAPS)-AIDS Research Group, Hospital Clinic, Catalonian Center for HIV Vaccines (HIVACAT) and University of Barcelona, Barcelona, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Álvarez-Fernández
authors.forename: Alberto
authors.initials: A
authors.lastname: Crespo Guardo
authors.forename: Javier
authors.initials: J
authors.lastname: García-Pérez
authors.forename: Felipe
authors.initials: F
authors.lastname: García
authors.forename: Julia
authors.initials: J
authors.lastname: Blanco
authors.forename: Laura
authors.initials: L
authors.lastname: Escribà-García
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Gatell
authors.forename: Jose
authors.initials: J
authors.lastname: Alcamí
authors.forename: Montserrat
authors.initials: M
authors.lastname: Plana
authors.forename: Sonsoles
authors.initials: S
authors.lastname: Sánchez-Palomino
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D015331:Cohort Studies; D057809:HEK293 Cells; D054303:HIV Reverse Transcriptase / Q000235:genetics; D006679:HIV Seropositivity / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000096:biosynthesis; D017384:Sequence Deletion; D014771:Virion / Q000276:immunology; D014779:Virus Replication
chemical_list: D016915:AIDS Vaccines; D007371:Interferon-gamma; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase